Based on the CSCO guidelines, NET may be considered in patients with hormone receptor–positive (HR+) breast cancer patients who require preoperative neoadjuvant therapy but are not candidates for chemotherapy, are temporarily ineligible for surgery, or do not require immediate surgery. The gene discussed is NR4A1; the disease is breast cancer.